2. Signaling Pathways
  3. GPCR/G Protein
  4. Platelet-activating Factor Receptor (PAFR)

Platelet-activating Factor Receptor (PAFR)

The platelet-activating factor receptor (PAFR) is a G-protein-coupled receptor involved in both normal physiological and numerous pathophysiological processes. PAFR responds to platelet-activating factor (PAF), a phospholipid mediator of cell-to-cell communication that exhibits diverse physiological effects. Stimulation of the PAFR via binding of platelet-activating factor (PAF) elicits diverse and potent biological activities and plays a profound role in acute inflammation, allergic disorders, endotoxic shock, and anaphylaxis. PAF is a potent and versatile mediator of inflammation that is produced by numerous cell types and tissues, and particularly by leukocytes.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-N0784
    Ginkgolide B
    		Antagonist 99.84%
    Ginkgolide B (BN-52021), a terpene lactone, is a potent platelet activating factor antagonist. Ginkgolide B protects endothelial cells via the activation of PXR from injuries induced by xeno- and endobiotics. Ginkgolide B can pass through the brain-blood barrier. Ginkgolide B has anti-oxidant, anti-inflammatory, anti-tumor, and anti-apoptotic activity. Ginkgolide B has marked neuroprotective effects against ischemia-induced impairments.
    Ginkgolide B
  • HY-108634
    Apafant
    		Antagonist 99.96%
    Apafant (WEB 2086), a chemical probe, is a potent platelet-activating factor (PAF) antagonist, inhibits PAF binding to human PAF receptors with a Ki of 9.9 nM. Apafant increases the gene expression of PAF-r, α-globin, β-globin, decreases the c-myb gene expression. Apafant shows a protective effect on alkyl-PAF-mediated lethalit.
    Apafant
  • HY-112825
    TSI-01
    		Inhibitor 98.52%
    TSI-01 is a pro-inflammatory phospholipid mediator that is rapidly synthesized by lyso-PAF acetyltransferase (lyso-PAFAT) in response to extracellular stimuli. Two types of lyso-PAFAT have been identified: lysophosphatidylcholine acyltransferase (LPCAT)1, which is mostly expressed in the lungs, and LPCAT2, which is expressed in inflammatory cells. TSI-01 is a selective inhibitor of LPCAT2 (IC50s=0.47 versus 3.02 μM for human LPCAT2 and LPCAT1, respectively). 60 μM it is shown to suppress PAF biosynthesis in mouse peritoneal macrophages stimulated with a calcium ionophore.
    TSI-01
  • HY-N2071
    Cedrol
    		99.76%
    Cedrol is a potent competitive inhibitor of cytochrome P-450(CYP) enzyme. Cedrol plays an anticancer role by inducing cell cycle arrest and Caspase-dependent apoptosis. Cedrol acts as a neutrophil agonist that can desensitize cells to subsequent stimulation of N-formyl peptides. Cedrol prevents neuropathic pain caused by chronic contractile injury by inhibiting oxidative stress and inflammation. In addition, Cedrol has antibacterial, hair loss prevention and anti-anxiety properties.
    Cedrol
  • HY-128694
    Foropafant
    		99.97%
    Foropafant (SR27417) highly potent, competitive, selective and orally active antagonist of platelet-activating factor (PAF) receptor, with a Ki value of 57 pM for [3H]PAF binding, at least 5-fold lower than that of unlabeled PAF itself. Foropafant potently inhibits PAF-induced aggregation of rabbit and human platelets.
    Foropafant
  • HY-116481
    Selenotifen
    		Antagonist
    Selenotifen (BN 52256) is an antiallergic agent. Selenotifen is a highly potent antagonist to PAF receptors. Selenotifen exhibits a statistically significant antiarrhythmic effect.
    Selenotifen
  • HY-19125
    BN-50726
    		Antagonist
    BN-50726 is a potent platelet-activating factor (PAF) receptor antagonist. BN-50726 inhibits PAF-induced effects (e.g., [3H]-serotonin release and hypotension) (IC50=5.40 nM). BN-50726 is promising for research of PAF-mediated pathological processes (e.g., inflammation, anaphylaxis, hypotension).
    BN-50726
  • HY-182583
    PAF antagonist-1
    		Antagonist
    PAF antagonist-1 is a platelet activating factor (PAF) receptor antagonist with a target Ki of 69 nM. PAF antagonist-1 inhibits PAF binding and displays enhanced affinity at A1, A2a, and A3 adenosine receptor subtypes compared to related dihydropyridine analogs with smaller ester groups. PAF antagonist-1 can be used for cardiovascular disorders, especially hypertension and coronary heart disease.
    PAF antagonist-1
  • HY-137257
    Carbamyl-PAF
    		Agonist 99.6%
    Carbamyl-PAF is an analog and agonist of platelet-activating factor (PAF). Carbamyl-PAF is not significantly metabolized by Raji lymphoblasts at 37°C, making it a useful tool for inflammation research. .
    Carbamyl-PAF
  • HY-130345
    PAF (C18)
    		99.89%
    C18-PAF, octadecane PAF, is the ligand of platelet-activating factor and PAF G protein-coupled receptor (PAFR). C18-PAF has renovasodilator properties and antihypertensive lipid properties. C18-PAF increases renal blood flow and causes dose-dependent systemic hypotension.
    PAF (C18)
  • HY-109897
    CV-6209
    		98.0%
    CV-6209 is a potent antagonist of platelet activating factor (PAF). CV-6209 inhibits the PAF-induced aggregation of rabbit and human platelets, with IC50s of 75 nM and 170 nM, respectively. CV-6209 can inhibit PAF-induced hypotension in rats.
    CV-6209
  • HY-114745
    MoTP
    		Antagonist 99.76%
    MoTP is a specific platelet activating factor receptor antagonist and can induce melanocyte ablation. MoTP can be used for the research of cancer.
    MoTP
  • HY-101833
    YM-264
    		99.24%
    YM-264 is a selective, potent and orally active platelet-activating factor (PAF) antagonist with a pKi value of 8.85 for rabbit platelet membranes.
    YM-264
  • HY-N1717
    2-Acetylbenzoic acid
    		Inhibitor 99.87%
    2-Acetylbenzoic acid, a Benzoic acid (HY-N0216) derivative, is a weak platelet aggregation inhibitor. 2-Acetylbenzoic acid inhibits Adenosine 5'-diphosphate (ADP, HY-W010918)-induced platelet aggregation.
    2-Acetylbenzoic acid
  • HY-141581
    Lyso-PAF C-18
    		99.7%
    Lyso-PAF C-18 is an intermediate for the synthesis of C18-PAF (HY-130345). It has an easily substituted "Lyso-PAF" structure and is easy to purify and has high yield. C18-PAF is a ligand for platelet-activating factor and PAF G protein-coupled receptor (PAFR) and has renovasodilator properties and antihypertensive lipid properties.
    Lyso-PAF C-18
  • HY-N10663
    Kadsurenone
    		Antagonist 99.78%
    Kadsurenone is a lignan with specific antagonistic activity against platelet-activating factor. Kadsurenone can be derived from the stem of Piper kadsura.
    Kadsurenone
  • HY-N7343
    Pregomisin
    		Antagonist 99.87%
    Pregomisin is a natural compound isolated from the fruits of Schizandra chinensis Baill. Pregomisin showed PAF antagonistic activity and the IC50 values were 48 μM.
    Pregomisin
  • HY-19121A
    TCV-309 chloride
    TCV-309 chloride is a potent and specific platelet activating factor (PAF) antagonist. TCV-309 chloride specifically inhibits PAF-induced aggregation of rabbit and human platelets, and [3H]PAF binding to rabbit platelet microsomes with IC50 values of 33 nM, 58 nM and 27 nM, respectively. TCV-309 chloride has beneficial effects in anaphylactic shock.
    TCV-309 chloride
  • HY-P2606
    Antiflammin 2
    		Inhibitor 99.50%
    Antiflammin 2 inhibits the synthesis of platelet-activating factor (PAF) with the IC50 of 100 nM.
    Antiflammin 2
  • HY-132190
    Hexanolamino PAF C-16
    		Antagonist 98%
    Hexanolamino PAF C-16 (1-O-hexadecyl-2-acetyl-sn-glycero-3-phospho (N,N,N trimethyl) hexanolamine) is a Platelet-activating Factor Receptor (PAFR) Modulator with partial agonist activity. Hexanolamino PAF C-16 induces platelet aggregation and macrophage production but fails to increase [Ca2+]i in platelets, suggesting that PAF receptors may interact with PAF receptors through Ca2+-dependent and -independent pathways. Related to platelet aggregation.
    Hexanolamino PAF C-16
Cat. No. Product Name / Synonyms Application Reactivity